Video
Fixed Duration Venetoclax Therapy in Relapsed/Refractory CLL
Author(s):
Centering focus on the relapsed/refractory setting of CLL, panelists consider the use of fixed-duration venetoclax following updated clinical trial data in this setting.
Transcript:
Sonali M. Smith, MD: We’re going to move to module 3 and discuss some of the emerging therapies that are coming up. At the beginning, when we were doing the CLL [chronic lymphocytic leukemia] overview, we heard that there are 3 buckets of agents. There are BTK [Bruton tyrosine kinase] inhibitors, BCL2 inhibitors, and monoclonal antibodies against CD20. What we haven’t covered is the fixed duration or indefinite therapy, but we’ve heard a little about the nuances of the different BTK inhibitors.
What we’re going to do now is switch and talk a little about the BCL2 inhibitors. Of course, the only 1 that’s FDA approved is venetoclax. I’m going to start with Susan to tell us about venetoclax. Give us a little background in terms of how it works and the role of fixed-duration, venetoclax-based monotherapy and combination therapies.
Susan M. O’Brien, MD: A lot of people are used to the fixed-duration regimens that we have now, but the original approval for venetoclax in relapsed CLL was as a continuous therapy. Like with the BTK inhibitors, it was given indefinitely until patients couldn’t tolerate it or developed resistance. It was extremely effective in that setting. There was a very important clinical trial designed specifically for patients failing B-cell receptor inhibitors, namely idelalisib-ibrutinib, and showing very good long-lasting remissions with continuous venetoclax in that setting. We can still use it like that to this day. Some people do, particularly in high-risk populations like patients with 17p deletion, where some people are concerned about fixed-duration therapy.
We then went on to have the MURANO trial, which was rituximab and venetoclax. That became an approved 2-year regimen for relapsed CLL. Then we got the CLL14 study, which we’ll talk about in a few minutes. That led to the approval of venetoclax and obinutuzumab in the frontline setting. [It lasted] for 1 year. Recently we saw at EHA [European Hematology Association Congress] data from the VeRVe study. That’s another real-world study that looked at the use of continuous venetoclax in the relapsed population. It recapitulated the original data from phase 1 very well. They had 70 or 80 patients, and about half of them had a 17p deletion or TP53 aberration. They showed very high response rates, about 75%, which is almost identical to what was seen in the original phase 1. These were very durable remissions. We tend not to use a continuous therapy anymore because people like the idea of fixed-duration regimens. Patients like that also, but it definitely can be given as continuous therapy to this day if one elects to do that.
Transcript edited for clarity.
